NCT01359956View on ClinicalTrials.gov

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma

PHASE3CompletedINTERVENTIONAL
Enrollment

269

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Malignant MelanomaRecurrent Melanoma
Interventions
DRUG

Dacarbazine

900 mg / m2 every 3 weeks

DRUG

Fotemustine

100 mg / m2 every 3 weeks

DRUG

Interferon Alfa-2b

5 M units every 3 weeks

All Listed Sponsors
lead

National Cancer Institute, Naples

OTHER

NCT01359956 - Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma | Biotech Hunter | Biotech Hunter